Counseling Patients With oHCM––Using Data to Instill Confidence
Back
oHCM Insights: Best Practices for Clinical Pharmacists in Targeted CMI Therapy
oHCM Insights: Best Practices for Clinical Pharmacists in Targeted CMI Therapy, features Andrew Willeford, PharmD, PhD, BCCP, and Laura Velazquez, PharmD, PhC, BCACP, in a peer-led conversation focused on optimizing management of obstructive hypertrophic cardiomyopathy (oHCM). The discussion centers on 3 themes: educating patients on the distinct pathophysiology of obstructive hypertrophic cardiomyopathy (oHCM) and the targeted mechanism of cardiac myosin inhibitors (CMIs), particularly mavacamten and newly approved aficamten; aligning clinical decision-making with long-term clinical trial and real-world REMS data demonstrating sustained efficacy, safety, and appropriate echocardiographic monitoring; and defining the clinical pharmacist’s leadership role in multidisciplinary care. Emphasis is placed on differentiating oHCM from non-obstructive disease, reinforcing patient confidence through robust real-world evidence, navigating REMS requirements, screening for CYP2C19 and CYP3A4 drug–drug interactions (including OTC products), incorporating pharmacogenomic considerations, coordinating echocardiogram monitoring, managing insurance barriers, and reducing physician burden through proactive, system-level execution of CMI programs.
oHCM Insights: Best Practices for Clinical Pharmacists in Targeted CMI Therapy
Episodes
All
All
Treatment Options for oHCM – Aligning Guidance With Real-World Data to Improve Outcomes
The Role of Clinical Pharmacists – Best Practices and Early Execution
Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP, breaks down the key distinctions between obstructive and nonobstructive hypertrophic cardiomyopathy (oHCM) and explains how cardiac myosin inhibitors target the underlying disease mechanism.
Craig Beavers explains how mavacamten's REMS program and its clearly defined echo-based monitoring protocols create a unique opportunity for pharmacists to take an active role in managing patients with obstructive hypertrophic cardiomyopathy (oHCM).
Craig Beavers discusses how mavacamten's established long-term safety data strengthen shared decision-making conversations, and outlines best practices for multidisciplinary collaboration when implementing cardiac myosin inhibitor therapy in patients with obstructive hypertrophic cardiomyopathy (oHCM).
Craig Beavers urges pharmacists to engage with obstructive hypertrophic cardiomyopathy (oHCM) management and explains how the alignment between mavacamten's clinical trial data and real-world outcomes validates its role as a safe, effective, and sustainable long-term therapy.
Advertisement
Advertisement